EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT

This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with chronic tophacaceous gout resistant to therapy with nonsteroidal anti-inflammatory drugs, glucocorticoids, and colchicine. The results show a good and long-term clinical ef...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Maksim Sergeyevna Eliseev, O V Zhelyabin, V G Barskova, E L Nasonov
Формат:	Artigo
Хэл сонгох:	Russo
Хэвлэсэн:	IMA PRESS LLC 2014-03-01
Цуврал:	Научно-практическая ревматология
Нөхцлүүд:	gout canakinumab arthritis, uric acid
Онлайн хандалт:	https://rsp.mediar-press.net/rsp/article/view/1365
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!